Adlyxin FDA Approval History
FDA Approved: Yes (First approved July 27, 2016)
Brand name: Adlyxin
Generic name: lixisenatide
Dosage form: Injection
Company: Sanofi
Treatment for: Diabetes, Type 2
Adlyxin (lixisenatide) is a once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus.
Development timeline for Adlyxin
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.